The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC.
We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.